1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A de novo supernumerary ring chromosome 1 causes B-cell acute lymphoblastic leukemia in monozygotic twins due to independent and partially convergent evolutionary trajectories
    Meeting Abstract

    Gutiérrez-Abril, J.; Gundem, G.; Fiala, E.; Liosis, K.; Farnoud, N.; Leongamornlert, D.; Amallraja, A.; Ossa, J. E. A.; Domenico, D.; Levine, M. F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes with MEK inhibitor therapy among adults with Langerhans cell histiocytosis (LCH): A multi-institutional study from the Adult LCH Working Group for the Histiocyte Society
    Meeting Abstract

    Goyal, G.; Acosta Medina, A. A.; Cao, X.; Bossert, D.; Matthew, P. C.; Makras, P.; Abdel-Wahab, O.; Abeykoon, J. P.; Amerikanou, R.; Bach, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • GLUT1 overexpression enhances 19-28z CAR-T cell expansion and metabolic fitness
    Meeting Abstract

    Shi, Y.; Kotchetkov, I. S.; Hanina, S. A.; Sadelain, M.
    Blood (2023)

    Fulltext@MSK | Save
  • Genetic alterations of follicular lymphoma can predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Fregonese, B.; Seshan, V.; Hajj, C.; Cederquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Use of a tissue-targeting recombinant human interleukin-22 fusion molecule (F-652) for the treatment of advanced refractory lower GI acute GVHD
    Meeting Abstract

    Satta, T.; Papadopoulos, E. B.; Gyurkocza, B.; Susman, P.; Singh, A.; Calafiore, M.; Giralt, S. A.; Perales, M. A.; Chen, J.; Li, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies
    Meeting Abstract

    Shahid, S.; Flynn, G. C.; Mauguen, A.; Bieler, J.; Prockop, S. E.; Scaradavou, A.; Boelens, J. J.; Sauter, C. S.; Perales, M. A.; Giralt, S. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Enhancing myeloid cancer genomic profiling through comprehensive whole genome sequencing using the Isabl GxT Heme analytical platform
    Meeting Abstract

    Deshpande, A. S.; Levine, M. F.; Hadi, K.; Gundem, G.; Patel, M.; Skrzypczak, S.; Kung, A. L.; Medina-Martínez, J. S.; Papaemmanuil, E.
    Blood (2023)

    Fulltext@MSK | Save
  • Single cell whole genome measurement of genomic heterogeneity and clonal evolution in multiple myeloma
    Meeting Abstract

    McPherson, A.; Maclachlan, K. H.; Myers, M.; Satas, G.; Landgren, O.; Usmani, S. Z.; Shah, S. P.; Maura, F.
    Blood (2023)

    Fulltext@MSK | Save